The FDA approval of Actelion’s
new pulmonary arterial
hypertension therapy Opsumit (PD
22 Oct), has reportedly made the
company a key takeover target.
Actelion’s existing product for the
PAH market, Tracleer, comes out of
patent in 2015 but the new product
has renewed interest from several
potential suitors including Bayer,
Novartis and GlaxoSmithKline,
according to a Bloomberg report.
The European Medicines Agency
has also recommended approving
the drug, with Actelion’s share price
up 62% so far this year.The above article was sent to subscribers in Pharmacy Daily's issue from 31 Oct 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Oct 13
THE 87-year-old Amcal group has refreshed its brand tagline to ‘For you, for life’, as unveiled yesterday to over 240 members, suppliers and partners at the group’s national retail conference in Sydney.
AMID yesterday’s Amcal brand refresh announcement (see page one), parent company Sigma Healthcare is also readying for the 01 Jul start of its wholesale supply contract with Chemist Warehouse Group, worth at least $3 billion in revenue in the first full year (PD 06 Jun 2023).
OVER a quarter of a million people have sbeen vaccinated against influenza this year through community pharmacies in Queensland, reported the Pharmacy Guild of Australia.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.